Syncom Formulations (India) Limited (SYNCOMF.NS)
INR 21.04
(-0.14%)
INR 21.04
(-0.14%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 210.81 Million INR | -0.56% |
| 2022 | 212 Million INR | 8.68% |
| 2021 | 195.06 Million INR | -13.52% |
| 2020 | 225.55 Million INR | 40.34% |
| 2019 | 160.72 Million INR | 17.11% |
| 2018 | 137.23 Million INR | 24.35% |
| 2017 | 110.36 Million INR | 10.26% |
| 2016 | 100.09 Million INR | -35.29% |
| 2015 | 154.68 Million INR | 41.41% |
| 2014 | 109.38 Million INR | 10.53% |
| 2013 | 98.96 Million INR | 62.91% |
| 2012 | 60.74 Million INR | 36.26% |
| 2011 | 44.58 Million INR | -61.21% |
| 2010 | 114.93 Million INR | 48.43% |
| 2009 | 77.43 Million INR | 181.86% |
| 2008 | 27.47 Million INR | -50.57% |
| 2007 | 55.57 Million INR | 62.65% |
| 2006 | 34.16 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 210.81 Million INR | 0.0% |
| 2023 FY | 210.81 Million INR | -0.56% |
| 2023 Q2 | 201.54 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 212 Million INR | 0.0% |
| 2022 FY | 212 Million INR | 8.68% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 204.64 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 196.3 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 195.06 Million INR | -13.52% |
| 2021 Q4 | 195.06 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 225.55 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 154.29 Million INR | 0.0% |
| 2020 FY | 225.55 Million INR | 40.34% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 172.61 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 160.72 Million INR | 17.11% |
| 2019 Q4 | 160.72 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 105.9 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 137.23 Million INR | 24.35% |
| 2018 Q4 | 137.23 Million INR | 0.0% |
| 2017 FY | 110.36 Million INR | 10.26% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 110.36 Million INR | 0.0% |
| 2016 Q4 | 100.09 Million INR | 0.0% |
| 2016 FY | 100.09 Million INR | -35.29% |
| 2015 FY | 154.68 Million INR | 41.41% |
| 2015 Q4 | 154.68 Million INR | 0.0% |
| 2015 Q2 | 117.13 Million INR | 0.0% |
| 2014 Q4 | 109.38 Million INR | 0.0% |
| 2014 Q2 | 140.23 Million INR | 0.0% |
| 2014 FY | 109.38 Million INR | 10.53% |
| 2013 Q4 | 98.96 Million INR | 0.0% |
| 2013 FY | 98.96 Million INR | 62.91% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 57.37 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 FY | 60.74 Million INR | 36.26% |
| 2012 Q2 | 119.85 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 60.74 Million INR | 0.0% |
| 2011 FY | 44.58 Million INR | -61.21% |
| 2010 FY | 114.93 Million INR | 48.43% |
| 2009 FY | 77.43 Million INR | 181.86% |
| 2008 FY | 27.47 Million INR | -50.57% |
| 2007 FY | 55.57 Million INR | 62.65% |
| 2006 FY | 34.16 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Sigachi Industries Limited | 707.2 Million INR | 70.19% |
| Ind-Swift Limited | 640.91 Million INR | 67.107% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 85.364% |
| Sakar Healthcare Limited | 277.32 Million INR | 23.982% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.785% |
| Innova Captab Limited | 1.44 Billion INR | 85.362% |
| Divi's Laboratories Limited | 31.84 Billion INR | 99.338% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 90.749% |
| Morepen Laboratories Limited | 2.48 Billion INR | 91.52% |
| Mankind Pharma Limited | 15.53 Billion INR | 98.643% |
| Sequent Scientific Limited | 3.46 Billion INR | 93.911% |
| Wanbury Limited | 360.23 Million INR | 41.478% |
| Laurus Labs Limited | 18.45 Billion INR | 98.858% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 97.027% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 96.837% |
| Alembic Limited | 113.4 Million INR | -85.904% |
| Hikal Limited | 3.03 Billion INR | 93.059% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 98.717% |
| Neuland Laboratories Limited | 3.5 Billion INR | 93.984% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 95.805% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 99.161% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 95.038% |
| Themis Medicare Limited | 705.74 Million INR | 70.129% |
| RPG Life Sciences Limited | 1.01 Billion INR | 79.127% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 99.388% |
| Lupin Limited | 49.53 Billion INR | 99.574% |
| Amrutanjan Health Care Limited | 289.04 Million INR | 27.065% |
| Wockhardt Limited | 6.4 Billion INR | 96.706% |
| Vaishali Pharma Limited | 3.79 Million INR | -5452.146% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 96.721% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -40.571% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 98.365% |
| FDC Limited | 3.88 Billion INR | 94.579% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.668% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -428.623% |
| Eris Lifesciences Limited | 1.89 Billion INR | 88.848% |
| Venus Remedies Limited | 1.21 Billion INR | 82.676% |
| ZIM Laboratories Limited | 812.62 Million INR | 74.058% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 82.202% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | -404.704% |
| Caplin Point Laboratories Limited | 3.63 Billion INR | 94.193% |
| Shilpa Medicare Limited | 3.44 Billion INR | 93.888% |
| Albert David Limited | 436.12 Million INR | 51.661% |
| Ajanta Pharma Limited | 8.28 Billion INR | 97.455% |
| Hester Biosciences Limited | 755.81 Million INR | 72.107% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 90.882% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 94.139% |
| Gufic Biosciences Limited | 2 Billion INR | 89.485% |
| Windlas Biotech Limited | 621.89 Million INR | 66.101% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 80.679% |
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | 39.204% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 82.949% |
| Granules India Limited | 13 Billion INR | 98.379% |
| Aarti Drugs Limited | 4.85 Billion INR | 95.661% |
| Bal Pharma Limited | 878.11 Million INR | 75.992% |
| Alkem Laboratories Limited | 26.61 Billion INR | 99.208% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.786% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | 72.681% |
| Medicamen Biotech Limited | 593.75 Million INR | 64.494% |
| Unichem Laboratories Limited | 7.04 Billion INR | 97.008% |
| Bafna Pharmaceuticals Limited | 296.41 Million INR | 28.879% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -726.823% |
| Valiant Laboratories Limited | 100.15 Million INR | -110.491% |
| Orchid Pharma Limited | 2.64 Billion INR | 92.021% |
| Medico Remedies Limited | 163.37 Million INR | -29.04% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -101.588% |
| Ipca Laboratories Limited | 24.71 Billion INR | 99.147% |
| Brooks Laboratories Limited | 96.1 Million INR | -119.352% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 99.075% |
| NATCO Pharma Limited | 7 Billion INR | 96.991% |
| Suven Life Sciences Limited | 7.08 Million INR | -2875.512% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -115.196% |
| Strides Pharma Science Limited | 11.26 Billion INR | 98.128% |
| Indoco Remedies Limited | 3.53 Billion INR | 94.029% |
| Alpa Laboratories Limited | 136.65 Million INR | -54.27% |
| Lasa Supergenerics Limited | 190.43 Million INR | -10.702% |
| Sun Pharma Advanced Research Company Limited | 14.79 Million INR | -1325.196% |